Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer (vol 26, pg 5544, 2008)

被引：0
|
作者：
Leo, Di
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 11期
关键词：
D O I：
10.1200/JCO.2009.22.9419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1923 / 1923
页数：1
相关论文
共 50 条
  • [21] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [22] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    British Journal of Cancer, 2004, 90 : 31 - 35
  • [23] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [24] A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
    Liu, Ke-Jun
    Guan, Zhong-Zhen
    Liang, Ying
    Yang, Xu-Qing
    Peng, Jin
    Huang, He
    Shao, Qing-Xiang
    Wang, Meng-Zhao
    Zhu, Yun-Zhong
    Wu, Chang-Ping
    Wang, Shao-Bin
    Xiong, Jian-Ping
    Bai, Yu-Xian
    Yu, Shi-Ying
    Zhang, Yang
    Hu, Xiao-Hua
    Feng, Ji-Feng
    Wu, Shi-Xiu
    Jiao, Shun-Chang
    Zhou, Cai-Cun
    Wang, Jie
    Wu, Hai-Ying
    ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (04) : 717 - 724
  • [25] Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    Ilhan, Yusuf
    Tatli, Ali Murat
    Teker, Fatih
    Onder, Arif Hakan
    Kose, Fatih
    Geredeli, Caglayan
    Karaagac, Mustafa
    Kaplan, Muhammet Ali
    Inanc, Mevlude
    Aydin, Sabin Goktas
    Kargi, Aysegul
    Arak, Haci
    Ozturk, Banu
    Besen, Ali Ayberk
    Selvi, Oguzhan
    Korkmaz, Mustafa
    Oruc, Zeynep
    Bozkurt, Oktay
    Bilici, Ahmet
    Bayram, Selami
    Dae, Shute Ailia
    Ozdogan, Mustafa
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 502 - 507
  • [26] A phase 3 randomized, double-blind trial comparing PF-05280014+paclitaxel vs. trastuzumab plus paclitaxel for treatment of HER2+metastatic breast cancer patients
    Ewesuedo, R.
    Barker, K. B.
    Taylor, C. T.
    Jacobs, I.
    CANCER RESEARCH, 2013, 73
  • [27] ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab plus paclitaxel and cisplatin (TP) versus placebo plus TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma
    Shen, Lin
    Lu, Zhihao
    Xu, Linxinyu
    Wang, Yan
    Zhou, Hui
    Liu, Ying
    CANCER RESEARCH, 2019, 79 (13)
  • [28] A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.
    Crown, J. P.
    Moulton, B.
    O'Donovan, N.
    CANCER RESEARCH, 2012, 72
  • [29] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Dent, Rebecca
    Oliveira, Mafalda
    Isakoff, Steven J.
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Saura, Cristina
    Wongchenko, Matthew J.
    Xu, Na
    Bradley, Denise
    Reilly, Sarah-Jayne
    Mani, Aruna
    Kim, Sung-Bae
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 377 - 386
  • [30] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Rebecca Dent
    Mafalda Oliveira
    Steven J. Isakoff
    Seock-Ah Im
    Marc Espié
    Sibel Blau
    Antoinette R. Tan
    Cristina Saura
    Matthew J. Wongchenko
    Na Xu
    Denise Bradley
    Sarah-Jayne Reilly
    Aruna Mani
    Sung-Bae Kim
    Breast Cancer Research and Treatment, 2021, 189 : 377 - 386
12345